RENEO PHARMACEUTICALS
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.
RENEO PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2014-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.reneopharma.com
Total Employee:
11+
Status:
Active
Contact:
+1 858-283-0280
Total Funding:
145 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
Niall O'Donnell Co-Founder, President, and CEO @ Reneo Pharmaceuticals
Co-Founder, President, and CEO
Alejandro Dorenbaum Chief Medical Officer @ Reneo Pharmaceuticals
Chief Medical Officer
Wendy Newman Head, Patient Engagement and Communications @ Reneo Pharmaceuticals
Head, Patient Engagement and Communications
Vinny Jindal Chief Financial Officer @ Reneo Pharmaceuticals
Chief Financial Officer
2021-03-01
Gregory Flesher President and CEO @ Reneo Pharmaceuticals
President and CEO
2020-11-01
Ashley Hall Chief Development Officer @ Reneo Pharmaceuticals
Chief Development Officer
2021-10-01
Wendy S. Johnson Chief Operating Officer @ Reneo Pharmaceuticals
Chief Operating Officer
Founder
Stock Details
Investors List
Pappas Capital
Pappas Capital investment in Series B - Reneo Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series B - Reneo Pharmaceuticals
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series B - Reneo Pharmaceuticals
Abingworth
Abingworth investment in Series B - Reneo Pharmaceuticals
Amzak Health Investors
Amzak Health Investors investment in Series B - Reneo Pharmaceuticals
Chiesi Ventures
Chiesi Ventures investment in Series B - Reneo Pharmaceuticals
RiverVest
RiverVest investment in Series B - Reneo Pharmaceuticals
Rock Springs Capital
Rock Springs Capital investment in Series B - Reneo Pharmaceuticals
Aisling Capital
Aisling Capital investment in Series B - Reneo Pharmaceuticals
Novo Ventures
Novo Ventures investment in Series B - Reneo Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-11 | Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer |
Official Site Inspections
http://www.reneopharma.com Semrush global rank: 2.4 M Semrush visits lastest month: 7.62 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Reneo Pharmaceuticals"
Reneo Pharmaceuticals and OnKure Announce …
May 13, 2024 Management and Organization. Following the merger, the combined company will be led by Nicholas Saccomano, Ph.D., President and …See details»
Reneo Pharmaceuticals - Crunchbase Company Profile …
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on …See details»
Reneo Pharmaceuticals - LinkedIn
Reneo Pharmaceuticals | 4,033 followers on LinkedIn. Reneo Pharmaceuticals is now OnKure Therapeutics, Inc.!See details»
Reneo Pharmaceuticals Management Team | Org Chart
Reneopharma.com; 1 949292XXXX; View Similar People. Related Companies GeneTex, Inc. 42 $26.6m Biomerica, Inc. 54 $14.6m Oncocyte Corporation. 84 $9m Zymo Research Corp. 193 …See details»
About RENEO PHARMACEUTICALS, INC. | DxMultiomics
Reneopharma.com. Mark. Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial …See details»
Reneo Pharmaceuticals acquired by OnKure Therapeutics
May 13, 2024 Acquiring Organization: OnKure Therapeutics OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers. Announced Date May 13, 2024; ... Reneopharma — Reneo Pharmaceuticals and OnKure Announce Proposed Merger .See details»
Reneo Pharmaceuticals - Overview, News & Similar companies
May 7, 2024 Reneo Pharmaceuticals contact info: Phone number: (858) 283-0280 Website: www.reneopharma.com What does Reneo Pharmaceuticals do? Reneo Pharmaceuticals is a …See details»
Reneo Pharmaceuticals - Pappas Capital
Dec 9, 2020 Reneo Pharmaceuticals is a clinical-stage start-up company, co-founded by Pappas Capital, focused on developing treatments for rare metabolic disordersSee details»
Reneo Pharmaceuticals - Company Profile & Staff Directory
Reneo Pharmaceuticals is a Biotechnology company located in 18575 Jamboree Rd, 275, Irvine, California 92612, US with 50 employees. Access Reneo Pharmaceuticals's email format and …See details»
Reneo Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Reneo Pharmaceuticals, Inc. of Irvine, CA. Get the latest business insights from Dun & Bradstreet.See details»
Reneo Pharmaceuticals - Craft
Reneo Pharmaceuticals is a pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. It develops REN001, a selective peroxisome …See details»
Reneo Pharmaceuticals Company Profile -Sales, Contacts, …
Reneo Pharmaceuticals, Inc. (trade name Reneo Pharmaceuticals) is in the Pharmaceutical Preparations business. View competitors, revenue, employees, website and phone number.See details»
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024 Management and Organization Following the merger, the combined company will be led by Nicholas Saccomano , Ph.D., President and Chief Executive Officer of OnKure, and …See details»
Reneo Pharmaceuticals announces reverse merger with OnKure
Jones Day represented Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical …See details»
Reneo Pharmaceuticals Company Overview, Contact Details
May 3, 2023 JDoe@reneopharma.com: 100%. See more formats. Frequently Asked Questions Where is Reneo Pharmaceuticals 's headquarters located? Reneo Pharmaceuticals 's main …See details»
Reneo Pharmaceuticals - Company Profile & Staff Directory
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their …See details»
Organization: Reneo Pharmaceuticals - Cbonds.com
Organization name. Reneo Pharmaceuticals Inc. Country name. USA Country of registration. USA. Industry. Pharmaceutical Preparation and Biotechnology. Bond debt - ...See details»
Reneo Pharmaceuticals Inc: Business Model, SWOT Analysis, and ...
Jun 24, 2024 Discover how Reneo Pharmaceuticals Inc is positioning itself in the competitive landscape of 2024 with an in-depth analysis of its business model, strengths, weaknesses, …See details»
Reneo Pharmaceuticals Inc. - Cruelty Free Investing
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops …See details»
Reneo Pharmaceuticals to Participate in Upcoming Investor
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the...See details»